4-(4-溴-2-氟苯基)苯磺酰氯 | 677326-82-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(4-溴-2-氟苯基)苯磺酰氯
• 英文名称: 4'-bromo-2'-fluorobiphenyl-4-sulfonyl chloride
• 英文别名: 4-(4-bromo-2-fluorophenyl)benzenesulfonyl chloride
• CAS: 677326-82-8
• 化学式: C₁₂H₇BrClFO₂S
• 分子量: 349.608
• InChiKey: HZKQJZCTZXUPIA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(4-溴-2-氟苯基)苯磺酰氯 在 苯甲醚 、 三乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 (S)-2-(4'-Bromo-2'-fluoro-biphenyl-4-sulfonylamino)-3-methyl-butyric acid
  参考文献：
  名称：

  一系列有效的，系统可用的联苯磺酰胺基质金属蛋白酶抑制剂的结构活性关系和药代动力学分析。

  摘要：

  制备了一系列（S）-2-（联苯基-4-磺酰基氨基）-3-甲基丁酸（5）的联苯磺酰胺衍生物，并评估了它们抑制基质金属蛋白酶（MMPs）的能力。对于这一系列化合物，我们的目标是用结构上不同的功能性系统取代取代基上5的联苯和α-位置的取代基，以评估这些变化对生物学和药代动力学活性的影响。随后的结构活性关系（SAR）研究表明，在4'-位（11c）处被溴取代的联苯磺酰胺显着提高了体外活性，并显示出优异的药代动力学（C（max），t（1/2），AUCs，相对于化合物5而言，可以通过用各种取代基取代11c的异丙基来改变α位的亲脂性，一般而言，与MMP-2，-3和-13相比，药效保持不变，但口服系统利用率较低。随后对其对映异构体11c'的评估表明，两种化合物都是同等有效的MMP抑制剂。相反，相应的异羟肟酸对映体对16a（S-异构体）和16a'（R-异构体）立体选择性抑制了MMP。在该系列中，16a'首次提

  DOI：

  10.1021/jm9903141
• 作为产物：
  描述：

  4-溴-2-氟联苯 在 N,N-二甲基甲酰胺 氯磺酸 、 氯化亚砜 作用下， 以 氯仿 为溶剂， 反应 8.0h， 生成 4-(4-溴-2-氟苯基)苯磺酰氯
  参考文献：
  名称：

  Development and Characterization of Biphenylsulfonamides as Novel Inhibitors of Bone Resorption

  摘要：

  Increased osteoclastic bone resorption plays a central role in the pathogenesis of many bone diseases, and osteoclast inhibitors are the most widely used treatments for these diseases. We have identified and characterized a series of novel biphenylsulfonamide derivatives that have potent inhibitory effects on osteoclastic bone resorption in vitro and that prevent ovariectomy-induced bone loss in vivo. A number of aromatic substituted derivatives were prepared and a QSAR model was generated, which allowed accurate prediction of compound potency. Using this model, we have prepared compounds able to inhibit osteoclast formation and bone resorption in vitro at concentrations in the nanomolar range. One such compound, 55 (ABD295) (Greig, I. R.; Mohamed, A. I.; Ralston, S. H.; van't Hof, R. J. Alkyl Aryl Sulfonamides as Therapeutic Agents for the Treatment of Bone Conditions. GB Patent WO2005118528, 2005), fully reversed ovariectomy-induced bone loss in mice at a dose of 5 (mg/kg)/day. In conclusion, biphenylsulfonamides like 55 form a new class of potent antiresorptive agents with possible therapeutic use in diseases characterized by increased bone resorption.

  DOI：

  10.1021/jm051236m

文献信息

• BENZOCYCLOHEPTENE ACETIC ACIDS
  申请人：Firooznia Fariborz

  公开号：US20120309796A1

  公开（公告）日：2012-12-06

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, asthma and COPD.

  本文提供的是化合物的公式(I)以及其药用盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗炎症性疾病和紊乱，如哮喘和慢性阻塞性肺病等，具有用处。
• Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions
  申请人：Ralston Stuart Hamilton

  公开号：US20080119555A1

  公开（公告）日：2008-05-22

  The present invention pertains to certain aryl alkyl sulfonamides and derivatives thereof which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption, and more particularly to compounds of the formula: wherein: Ar 1 is independently C 5-20 aryl (e.g., biphenyl, phenanthryl, fluorenyl, or carbazolyl, most preferably biphenyl), and is optionally substituted; R N is independently —H, acyl, C 5-20 aryl-C 1-7 alkyl, C 3-20 heterocyclyl, or C 1-7 alkyl, and is optionally substituted; R alk is a C 2-10 alkylene group, and is optionally substituted; and Q is independently —H or an organic group having from 1 to 30 atoms selected from carbon, nitrogen, oxygen, sulfur, phosphorus, fluorine, chlorine, bromine, and iodine (e.g., an oxy-type group, an amine-type group, etc.); and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit osteoclast survival, formation, and/or activity, and to inhibit conditions mediated by osteoclasts and/or characterised by bone resorption, in the treatment of bone disorders such as osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, and the like; and/or in the treatment of conditions associated with inflammation or activation of the immune system.

  本发明涉及某些芳基烷基磺酰胺及其衍生物，其中，它们抑制破骨细胞的存活、形成和/或活性；和/或抑制骨吸收，更具体地说，是式子的化合物： 其中：Ar1独立地是C5-20芳基（例如，联苯、菲、芴或咔唑基，最好是联苯），并且可以选择性地被取代；RN独立地是-H、酰基、C5-20芳基-C1-7烷基、C3-20杂环基或C1-7烷基，并且可以选择性地被取代；Ralk是C2-10烷基链，可以选择性地被取代；Q独立地是-H或具有1-30个由碳、氮、氧、硫、磷、氟、氯、溴和碘选择的有机基团（例如，氧型基团，胺型基团等）；以及其药学上可接受的盐、溶剂化合物、酰胺、酯、醚、化学保护形式和前药。本发明还涉及包含这样的化合物的制药组合物，以及在体外和体内使用这样的化合物和组合物来抑制破骨细胞的存活、形成和/或活性，并抑制由破骨细胞介导和/或通过骨吸收表征的骨疾病的治疗，例如骨质疏松症、类风湿性关节炎、与癌症相关的骨疾病、帕吉特病等；和/或用于治疗与炎症或免疫系统激活有关的疾病。
• [EN] ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS<br/>[FR] ARYLE-ALKYLE SULFONAMIDES UTILISES EN TANT QU'AGENTS THERAPEUTIQUES POUR LE TRAITEMENT DE PATHOLOGIES OSSEUSES
  申请人：UNIV ABERDEEN

  公开号：WO2005118528A3

  公开（公告）日：2006-01-26
• US7964643B2
  申请人：——

  公开号：US7964643B2

  公开（公告）日：2011-06-21
• [EN] BENZOCYCLOHEPTENE ACETIC ACIDS<br/>[FR] ACIDE ACÉTIQUE DE BENZOCYLCOHEPTÈNE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012168162A1

  公开（公告）日：2012-12-13

  Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, asthma and COPD.